Tokyo, Japan
Tokyo, Japan

Fujifilm Holdings Corporation, commonly known as Fujifilm, is a Japanese multinational photography and imaging company headquartered in Tokyo, Japan.Fujifilm's principal activities are the development, production, sale and servicing of color film, digital cameras, photofinishing equipment, color paper, photofinishing chemicals, medical imaging equipment, graphic arts equipment and materials, flat panel displays, optical devices, photocopiers and printers. Wikipedia.


Time filter

Source Type

A photoelectric conversion element, a dye-sensitized solar cell, and a metal-complex pigment, pigment solution, and terpyridine compound or esterified terpyridine compound used therein. The photoelectric conversion element has an electrically-conductive support, an electrolyte-containing photoreceptor layer, an electrolyte-containing charge-transfer layer, and a counter electrode. The photoreceptor layer contains semiconductor microparticles on which a metal-complex pigment that can be represented by a specific formula (1) is supported.


Provided are a transdermal absorption sheet capable of suppressing a sheet portion from being curled and of improving impact resistance of the sheet portion, and a method of manufacturing the transdermal absorption sheet, capable of suppressing a sheet portion from being curled in drying and of shortening a time required for drying a base material liquid. A transdermal absorption sheet 10 includes: a sheet portion 14; a plurality of needle-like protruding portions 12 that are arranged on one surface of the sheet portion 14; and a sheet-like mesh structure body 16 that is included in the sheet portion 14 and that has an area, in a plan view, including at least a part of a region S in which the plurality of needle-like protruding portions 12 are arranged.


There is provided a method capable of manufacturing a mold at low cost, and a method of manufacturing a biocompatible pattern sheet by using the mold. The method of manufacturing a mold 68 having a recessed pattern 70 includes the steps of: forming a silicone resin film 60 by applying a silicone resin solution 58 to a surface of a model 40 having a protrusion pattern 42; defoaming the silicone resin film 60 by reducing the silicone resin film 60 in pressure; forming the mold 68 by heating and curing the silicone resin film 60 while a base plate 64 is in contact with a face of the silicone resin film 60, the face being opposite to the model 40; and releasing the mold 68 from the model 40 after releasing the base plate 64. The method of manufacturing a pattern sheet 76 uses the mold 68.


An object of the present invention is to provide a cell structure for brain damage treatment which does not contain glutaraldehyde and in which it is possible to exhibit a sufficient effect of treating brain damage, a production method thereof, and a brain damage treatment agent. According to the present invention, there is provided a cell structure for brain damage treatment which contains biocompatible macromolecular blocks and at least one kind of cell and in which a plurality of the biocompatible macromolecular blocks are disposed in gaps between a plurality of the cells, in which the tap density of the biocompatible macromolecular block is 10 mg/cm^(3) to 500 mg/cm^(3) or a value obtained by dividing a square root of a cross-sectional area in a two-dimensional cross-sectional image of the biocompatible macromolecular block by a peripheral length is 0.01 to 0.13.


Patent
Fujifilm Co. | Date: 2017-03-08

A method for preparing an ionically-charged membrane comprising the steps (1) applying a film of curable composition to a support; (2) curing the film of curable composition to give anionically-charged membrane; and (3) removing the ionically-charged membrane from the support; wherein the curable composition comprises a) 5 to 50wt% of curable compound comprising one ethylenically unsaturated group and anionic group; b)10 to 70wt% of crosslinking agent comprising at least two ethylenically unsaturated groups and having a molecular weight of at least 500 dalton per ethylenically unsaturated group; and c) 5 to 60wt% of inert solvent.


Patent
Fujifilm Co. | Date: 2017-04-05

In an embodiment, a probe device includes a portion having a curved surface and a plurality of tiles variously coupled to the curved surface. The tiles each include a plurality of piezoelectric transducer elements and a base adjoining and supporting the plurality of piezoelectric transducer elements. The probe device further comprises curved lens portions each coupled to a respective one of the plurality of tiles, wherein for each of the tiles, the plurality of piezoelectric transducer elements of the tile are to propagate a wave toward the respective curved lens portion. In another embodiment, the probe device further comprises a sheath material surrounding the curved lens portions.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: NMP-24-2015 | Award Amount: 7.95M | Year: 2016

Shortage of fresh water has become one of the major challenges for societies all over the world. Water desalination offers an opportunity to significantly increase the freshwater supply for drinking, industrial use and irrigation. All current desalination technologies require significant electrical or thermal energy, with todays Reverse Osmosis (RO) desalination units consuming electric energy of at least 3 kWh/m3 in extensive tests about ten years ago, the Affordable Desalination Collaboration (ADC) in California measured 1.6 kWh/m3 for RO power consumption on the best commercially available membranes, and total plant energy about twice as high. To overcome thermodynamical limitations of RO, which point to 1.09 kwh/m3 for seawater at 50 % recovery, Microbial Desalination Cells (MDC) concurrently treat wastewater and generate energy to achieve desalination. MDCs can produce around 1.8 kWh of bioelectricity from the handling of 1 m3 of wastewater. Such energy can be directly used to i) totally remove the salt content in seawater without external energy input, or ii) partially reduce the salinity to lower substantially the amount of energy for a subsequent desalination treatment. MIDES aims to develop the Worlds largest demonstrator of an innovative and low-energy technology for drinking water production, using MDC technology either as stand-alone or as pre-treatment step for RO. The project will focus on overcoming the current limitations of MDC technology such as low desalination rate, high manufacturing cost, biofouling and scaling problems on membranes, optimization of the microbial-electrochemical process, system scaling up and economic feasibility of the technology. This will be achieved via innovation in nanostructured electrodes, antifouling membranes (using nanoparticles with biocide activity), electrochemical reactor design and optimization, microbial electrochemistry and physiology expertise, and process engineering and control.


Grant
Agency: European Commission | Branch: H2020 | Program: IA | Phase: NMP-24-2015 | Award Amount: 9.80M | Year: 2016

The REvivED water project will establish electrodialysis (ED) as the new standard providing a source of safe, affordable, and cost-competitive drinking water, using less than half the energy required by state-of-the-art Reverse Osmosis (RO) plants. The innovations of the project constitute a technology platform with a very wide field of potential applications. All components and systems have reached at least TRL4 and will be further developed reaching at least TRL7. The main focus of the project will be on the following applications: 1. A simplified ED system that can be used for brackish water desalination (8 pilots in developing countries) or for tap-water softening (2 pilots in Germany and the Netherlands). 2. A multistage ED system for industrial-scale seawater desalination, which will be demonstrated to reach energy consumption as low as 1.5 kWh/m3 (1 pilot in the Netherlands). 3. Combinations of the multistage ED system with the latest salinity gradient power systems (Reverse ElectroDialysis - RED), which can further reduce energy consumption for seawater desalination to the region of 1 kWh/m3 (1 pilot in the Netherlands). 4. The versatile nature of the developed innovations will be demonstrated by testing their combinations with Reverse Osmosis (RO) systems (1 pilot in Spain). This will allow initial market introduction, without the need to replace the extensive RO infrastructure. The pilot systems in developing countries will be located in critical areas where the project partner PHAESUN has local offices in Africa (Eritrea, Ivory Coast, Somalia, Djibouti and Ethiopia), Asia (Dubai, and India) and Latin America (Panama). The consortium brings together leading partners covering the whole value chain and ensuring exploitation of the results. It is clearly industry driven, and it gives European industry the chance to take the lead of the ED revival and face the competition from the US that is also actively pursuing this important growth market.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-1-2014 | Award Amount: 3.53M | Year: 2016

Separation and purification of biopharmaceuticals is today one of the most time and cost intense Downstream Processing (DSP) operations in the manufacture of commercial products. Separation and purification of proteins is usually achieved chromatographically, with all of its disadvantages including high buffer requirements, large footprint, reuse and storage of resin studies as well as costs. Traditional DSP based on batch chromatography contribute ca. 66% of the total production cost of anti-cancer monoclonal antibodies (mAbs). Largely contributing to this is the cost of chromatography media; for instance, the cost of 1 L of protein A resin with binding capacity of 20-70 g mAb is about 25000 Eur. By a visionary and ambitious combination of the emerging Continuous Manufacturing Paradigm with innovative Membrane Crystallization Technology and the selective nanotemplate-recognitions directly from the fermentation broth, the AMECRYS Network aims to develop a new Continuous Template-Assisted Membrane Crystallizer in order to revolutionize the DSP platform for mAbs production, thus achieving unprecedented purification and manufacturing efficiencies. Major research challenges will include: i) the synthesis of 3D-nanotemplates with specific molecular recognition ability towards mAbs from complex solutions; ii) the development of tailored macroporous fluoropolymer membranes for advanced control of selective heterogeneous nucleation; iii) the design of multilevel microfluidic devices for high-throughput mAb crystallization screening in a wide range of conditions under continuous flow (pharma-on-a-chip concept); iv) technology scale-up to a L-scale continuous prototype designed with recognition of QS/GMP compliance for biopharmaceuticals. The replacement of chromatography with a single membrane-crystallization unit will lead to >60% CapEx and O&M costs decrease, 30-fold footprint reduction and high-purity solid formulation of mAbs with preserved biological activity.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: LCE-24-2016 | Award Amount: 4.99M | Year: 2016

Membrane separation processes can be applied to many capture processes from Pre-Combustion ( CO2-H2 / CO2-CH4 separation) to Post-Combustion (CO2-N2) and Oxyfuel (O2-N2) and are generally endowed with high flexibility and potentially low operative costs with respect to other capture methods. However the current materials are still lacking of separation performance and durability suitable for an efficient and economically feasible exploitation of such technology. The Project NANOMEMC2 aims in overcoming the current limitation focusing on the development of innovative CO2 selective membranes with high flux and selectivity suitable for application to both Pre and Post-combustion Capture processes. To that aim nanocomposite or mixed matrix membranes will be considered with particular focus on facilitated transport mechanisms promoted by carrier attached to the polymer or the filler. Graphene based nanosheets and cellulose nanofibres will be studied in detail considering their possible modification to improve polymer compatibility and affinity with CO2. A new generation of Facilitated Transport Mixed Matrix ( FTMM) membranes for CCS applications will be developed with increased CO2 flux and selectivity beyond the current target for industrial deployment of carbon capture membrane technologies

Loading Fujifilm Co. collaborators
Loading Fujifilm Co. collaborators